Clinical Innovations Expands Labor and Delivery Portfolio with Its First Neonatal Product Acquisition
Leading healthcare manufacturer acquires babyLance™ safety heelstick
from MediPurpose™
SALT LAKE CITY–(BUSINESS WIRE)–Clinical
Innovations, the largest medical device company exclusively focused
on labor and delivery, today announced that it has acquired the
babyLance™ safety heelstick device from MediPurpose™, a Singapore-based
medical products company.
The babyLance™ safety heelstick is a safe and precise heel incision
device for use with premature infants, newborns and toddlers. Designed
by neonatal caregivers, babyLance™ uses an innovative spring mechanism
and ergonomic design to allow for safe, stable, accurate sampling and
minimal discomfort for babies. The full babyLance™ portfolio contains
four CLSI LA4-A5-compliant devices with varied incision depths for
babies weighing anywhere from less than 1,000 grams to more than nine
kilograms.
“The innovative babyLance™ safety heelstick was designed by the neonatal
nurses who use it every day and understand the importance of safety and
accuracy needed for obtaining blood for testing. The arching mechanism
of the device reduces the pain and invasiveness of this commonly
performed procedure,” said Ken Reali, president and CEO of Clinical
Innovations. “With our focus on improving the lives of mothers and their
babies, we’re proud to introduce babyLance™ as our first neonatal device
and a core part of our labor and delivery product portfolio. This
acquisition is an important step in our strategy to expand into the
NICU.”
As Clinical Innovations’ first neonatal acquisition, babyLance™ adds to
the company’s continually growing medical device portfolio, which also
includes the Kiwi® Vacuum-Assisted Delivery System, the traxi®
Panniculus Retractor and other labor and delivery products designed to
improve the lives of mothers and their babies throughout the world.
“Clinical Innovations is a market leader in labor and delivery because
it’s always looking at new products and areas where innovation makes the
difference,” said Mike Lynch, operating partner for Pritzker Group
Private Capital. “As a leading neonatal device, babyLance™ is a great
fit in an important adjacent market for Clinical Innovations.”
Originally launched by MediPurpose™ in 2010, babyLance™ was relaunched
in 2012 with an improved design after extensive product definition and
validation by neonatal nurses. The new babyLance™ includes an improved
“pull” spring mechanism and optimized incision profile. Today the device
is sold primarily in the U.S., European and Chinese markets.
Clinical Innovations is a member of Pritzker Group’s family of companies.
About Clinical Innovations
Clinical Innovations is the largest medical device company exclusively
focused on labor and delivery. Already a market leader in several
categories with products such as the Koala® Intrauterine Pressure
Catheter; Kiwi® Vacuum-Assisted Delivery System; ROM Plus® Rupture of
Membranes Test; traxi® Panniculus Retractor and ClearView Uterine
Manipulator. Clinical Innovations is expanding its global presence while
directly researching and developing state-of-the-art technologies and
innovative medical devices that fulfill its mission of improving the
lives of mothers and their babies throughout the world. Clinical
Innovations is a Pritzker Group company. For more information, visit clinicalinnovations.com.
About Pritzker Group
Pritzker Group, led by Tony and J.B. Pritzker, has three principal
investment teams: Private Capital, which acquires and operates leading
North America-based companies; Venture Capital, which provides
early-stage and growth venture funding to technology companies
throughout the United States; and Asset Management, which partners with
top-performing investment managers across global public markets.
Pritzker Group Private Capital acquires North America-based
middle-market companies with leading positions in the manufactured
products, services and healthcare sectors. The firm’s permanent,
proprietary capital base allows for efficient decision making, broad
flexibility with transaction structure and investment horizon, and
alignment with management teams focused on creating long-term value.
Pritzker Group brings significant resources, expertise and credibility
in building businesses and is an ideal partner for entrepreneur- and
family-owned companies. For more information, visit pritzkergroup.com.
Contacts
Martha Arendt, Aileron Communications
312.629.9400, marendt@aileroninc.com
